AbCellera Biologics (ABCL) Equity Ratio (2020 - 2026)

AbCellera Biologics has reported Equity Ratio for 7 years, with the latest figure at 0.72 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 5.7% year-over-year to 0.72; the trailing twelve-month figure through Mar 2026 stood at 0.72 (down 5.7% YoY), and the FY2025 full-year result was 0.71, down 8.2% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.72, up from 0.71 in the prior quarter.
• The five-year high for Equity Ratio was 0.81 in Q1 2023, with the low at 0.71 in Q3 2025.
• Historically, Equity Ratio has averaged 0.76 across 5 years, with a median of 0.77 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio declined 10.59% — and 2023, when it increased 6.39%.
• AbCellera Biologics' Equity Ratio stood at 0.8 in 2022, then dropped by 3.25% to 0.77 in 2023, then climbed by 0.24% to 0.78 in 2024, then fell by 8.2% to 0.71 in 2025, then climbed by 0.72% to 0.72 in 2026.
• The last three Equity Ratio figures came in at 0.72 (Q1 2026), 0.71 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.